9 Facts About HRT and Blood Clot Risk That Depend Entirely on the Route of Delivery
So many women have been told 'HRT raises your clot risk' and walked away thinking the decision was made for them. What nobody mentioned was that the patch, gel, or spray they might have been offered carries a clotting profile that looks completely different from a tablet. That single omission has kept a lot of women suffering unnecessarily — and that feels like a real failure of care.
Learn more about Rose →Oral estrogen triggers a 'first-pass' effect through the liver that transdermal estrogen bypasses entirely
When estrogen is swallowed, it travels through the gut and into the liver before reaching the bloodstream — a process called hepatic first-pass metabolism. This liver passage stimulates the production of clotting factors, including Factor VII and fibrinogen, as well as C-reactive protein. Transdermal estrogen — delivered through patches, gels, or sprays — absorbs directly into the bloodstream through the skin, completely skipping this liver activation and leaving clotting factor production largely undisturbed.
Oral estrogen roughly doubles the risk of venous thromboembolism (VTE); transdermal estrogen does not appear to increase it
Multiple large observational studies, including the ESTHER study and a meta-analysis published in the British Medical Journal, have consistently shown that oral estrogen is associated with approximately a two-fold increase in VTE risk compared to non-users. The same body of evidence shows transdermal estrogen at standard doses carrying no statistically significant increase in VTE risk. This is not a small or contested difference — it has been replicated across populations and study designs.
The absolute risk increase from oral HRT is still small for healthy women — but 'small' is not 'zero'
In women aged 50–59 with no prior VTE history, the background risk of a blood clot is roughly 1–2 per 1,000 women per year. Oral estrogen roughly doubles that, bringing it to around 2–4 per 1,000. For an individual healthy woman, this remains a low absolute risk — but for women who already carry thrombotic risk factors such as obesity, limited mobility, or clotting disorders, that doubling can tip the calculation meaningfully. Transdermal estrogen removes this variable almost entirely.
Women with a history of VTE or a known thrombophilia are not automatically excluded from HRT — but route of delivery becomes critical
Guidelines from the British Menopause Society and NICE specifically note that transdermal estrogen may be appropriate even for women with a personal or family history of VTE, subject to specialist assessment. This is a significant departure from older guidance that treated any clot history as a blanket contraindication to all HRT. The logic is grounded in the evidence: if the risk is route-dependent, removing the high-risk route opens a door that many women and clinicians assumed was permanently closed.
The type of progestogen used alongside estrogen also influences clot risk, independent of the estrogen route
Synthetic progestogens — particularly medroxyprogesterone acetate (MPA) and norethisterone — have been associated with additional increases in VTE risk when combined with estrogen. Micronised progesterone (body-identical progesterone), by contrast, appears to be neutral with respect to clotting risk in most current evidence. This means that optimising HRT safety involves considering both the estrogen delivery route and the type of progestogen — they are separate variables with separate risk profiles.
BMI significantly modifies the absolute risk picture, and this interacts with route of delivery in ways worth understanding
Higher BMI is an independent risk factor for VTE, and some data suggest that the relative risk increase from oral estrogen is amplified in women with obesity. The ESTHER study found that among women with a BMI over 25, the combination of oral estrogen and inherited thrombophilia produced substantially elevated risk. Transdermal estrogen did not show this interaction in the same dataset, reinforcing the case for non-oral routes in women where weight-related VTE risk is already elevated.
This distinction is not yet consistently communicated at the point of prescribing, and that gap has real consequences
Surveys of women's experiences with HRT consultations in the UK and elsewhere consistently show that many women are told about blood clot risk as a general feature of HRT, without being told that the risk is largely specific to oral administration. This leads some women to decline all forms of HRT unnecessarily, while others take oral forms without awareness that a lower-risk alternative exists. The information asymmetry is not a trivial issue — it directly affects whether women receive appropriate care.
Estradiol dose through the transdermal route matters — very high doses may partially close the risk gap
The neutral clotting profile of transdermal estrogen is most clearly demonstrated at standard therapeutic doses (typically 50–100 micrograms for patches, or equivalent gel doses). At supraphysiological doses, the evidence base is thinner, and it would be premature to assume complete risk neutrality across all dose levels. For most women using transdermal HRT within standard licensed ranges, current evidence supports a benign clotting profile — but dose is worth discussing with a prescriber, particularly if upward titration is being considered.
Understanding route-dependent risk reframes HRT decision-making from 'is it safe?' to 'which form is right for this person?'
The binary framing of HRT as either safe or unsafe obscures a more useful clinical question: which delivery route, which estrogen type, and which progestogen gives this individual the best balance of symptom relief and risk profile. For many women — including those with moderate VTE risk factors — transdermal estrogen combined with micronised progesterone represents a well-evidenced option with a genuinely favourable risk-benefit ratio. Getting to that conversation requires that both women and clinicians understand that not all HRT carries the same clot risk.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.